Scinvivo is developing an imaging platform built around a forward-looking OCT catheter that visualizes human morphological tissue structure a few millimetres deep at high resolution. The company aims to make cancer diagnostics faster and more accurate, reduce unnecessary surgeries, and enable more precise minimally invasive procedures and personalized treatment. It has closed a €4.7 million financing comprising equity investment and an Innovatiekrediet loan from the Netherlands Enterprise Agency (RvO). Scinvivo will use the funds to improve the catheter, OCT system, and software so the product is clinic-ready and appealing to urologists, and to perform clinical trials to prove clinical benefits. The team will also prepare documentation to obtain CE certification and develop a go-to-market strategy to launch the OCT imaging platform commercially. Bladder cancer has been chosen as the first clinical indication, with reviewers seeing the technology as a potential game changer in diagnostic routines.

Total raised

$5M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2024